VFM
NVCR icon

Vision Financial Markets’s NovoCure NVCR Stock Holding History

Vision Financial Markets’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50
Closed -$890 – 447
2025
Q2 		$890 Hold
50
– – ﹤0.01% 371
2025
Q1 		$891 Buy
+50
New +$1.14K ﹤0.01% 360

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vision Financial Markets's NVCR Position: Q3 2025 in Review

Vision Financial Markets sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 50 shares — an estimated $890 sold.

Vision Financial Markets first reported a position in NVCR in Q1 2025 and held it in 2 quarters. The position peaked at $891 in Q1 2025. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Vision Financial Markets reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Vision Financial Markets sold 50 NovoCure shares in Q3 2025, an estimated $890.
  • Vision Financial Markets first reported a position in NovoCure in Q1 2025 and held it in 2 quarters.
  • Vision Financial Markets's NovoCure position peaked at $891 in Q1 2025.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Vision Financial Markets's 13F filing for Q3 2025, filed 6 Nov 2025.